Effectiveness and Tolerability of аgomelatine in the Treatment of Patients With Depression After SARS-CoV-2 (TELESPHOR)
Не применимо
Завершено
NCT05323994
| Заболевание | Depression, COVID-19 |
|---|
| Фаза | Не применимо |
|---|
| Спонсор | Servier Russia |
|---|
| Статус | Завершено |
|---|
| Участники | 104 участн. |
|---|
| Дата начала | 19.04.2022 |
|---|
| Дата завершения | 20.02.2023 |
|---|
| Публикация результатов | 17.10.2024 |
|---|
Кратко
This is a multi-centre, observational, non-interventional study, which will prospectively collect clinical and socio-demographic data from patients with depression occurred after COVID 19 in real clinical settings during 8 weeks of treatment. 10 clinics and 10 of psychiatrists and neurologists across the country will participate in the study and it is estimated that each investigating physician will enroll 10 patients.
Antidepressive Effectiveness of Agomelatine in Patients With Depression Episode Occurred After COVID-19 Assessed by HAMD-17 After 8 Weeks of Treatment in the Daily Clinical Practice.
8 weeks · score on a scale
| Patients With Depression Occurred After COVID 19 | 10.9 ± 4.90 score on a scale |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.